Seres Therapeutics (NASDAQ:MCRB) Lowered to “Sell” Rating by StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

Other equities research analysts have also recently issued research reports about the stock. The Goldman Sachs Group lowered their price target on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a report on Friday, March 14th. Chardan Capital reissued a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research report on Thursday, March 20th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $4.00.

Seres Therapeutics Stock Performance

Shares of MCRB stock opened at $0.59 on Thursday. The firm has a market cap of $102.96 million, a price-to-earnings ratio of -2.57 and a beta of 2.54. Seres Therapeutics has a 52 week low of $0.46 and a 52 week high of $1.53. The firm’s 50-day simple moving average is $0.72 and its two-hundred day simple moving average is $0.79.

Institutional Trading of Seres Therapeutics

Institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its holdings in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after acquiring an additional 788,762 shares during the period. Jane Street Group LLC grew its position in shares of Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 37,866 shares in the last quarter. Northern Trust Corp grew its position in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 44,461 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 121,793 shares during the period. Finally, Avantax Advisory Services Inc. lifted its holdings in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.